GordonMD Global Investments reports $16 million Pyxis Oncology common share purchase
Bitget2026/10/02 12:36- GordonMD Global Investments, a 10% owner of Pyxis Oncology, disclosed a purchase of 5,517,000 common shares.
- Beneficial ownership rose to 15,541,909 shares, held indirectly through GordonMD Long Biased Master Fund.
- The filing also reports the purchase of 7,546,766 common stock purchase warrants with a $3.50 exercise price.
- Warrants are not exercisable until stockholder approval increases authorized common shares.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like

Bitcoin rebounds sharply from oversold levels, briefly surpassing $57,000

Masayoshi Son's Trillion-Dollar Gamble: Once Considered Acquiring SK Hynix
According to reports, Masayoshi Son once planned to acquire the South Korean memory chip giant SK Hynix for nearly 1 trillion US dollars and had approached Wall Street institutions to seek financing, but SoftBank has confirmed it is no longer actively pursuing the deal. The massive financing requirement and South Korean regulatory restrictions were major obstacles. This plan also highlights SoftBank’s further strategic intention to invest in AI storage chips.
"Sell-offs bring more sell-offs! Goldman Sachs predicts another large-scale sell-off in the U.S. stock market in the coming week."
Goldman Sachs stated that the bank’s “panic index” has risen to 9 out of 10, with systemic selling pressure continuing to spread. In the coming week, CTAs may sell up to $80.6 billion in US stocks, and even if the market remains flat, there is still $65.8 billion in sell orders waiting to be executed. The Anthropic IPO failed to boost market risk appetite, and concerns over AI investment returns continue to weigh on tech stock valuations.